Elocon

Mometasone furoate.

Each gram of Elocon lotion, cream and ointment contains mometasone furoate 1 mg.

Mometasone furoate, a synthetic corticosteroid, exhibits anti-inflammatory, antipruritic and vasoconstrictive properties.

Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses eg, psoriasis and atopic dermatitis.

Lotion: Apply a few drops to affected skin areas once daily; massage gently and thoroughly until the medication disappears.
Cream/Ointment: Apply a thin film to the affected skin areas once daily.
Do not use occlusive dressing.

Patients who are sensitive to mometasone furoate, to other corticosteroids or to any component of Elocon.

If irritation or sensitization develops with the use of Elocon, treatment should be discontinued and appropriate therapy instituted.
In the presence of an infection, use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection is controlled adequately.
Elocon is not for ophthalmic use.
Use in pregnancy & lactation: Since safe use of Elocon in pregnant women has not been established, topical corticosteroids should be used during pregnancy only if the potential benefit justifies potential risk to the fetus. Drugs of this class should not be used on pregnant patients in large amounts or for prolonged periods of time. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in the breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Use in children: Any of the side effects that have been reported following systemic use of corticosteroid including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.
Systemic absorption of topical corticosteroids will be increased if extensive body surface areas are treated or if the occlusive technique is used. Suitable precautions should be taken under these conditions or when long-term use is anticipated, particularly in infants and children. Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Use of topical corticosteroids in children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with growth and development of children.

Since safe use of Elocon in pregnant women has not been established, topical corticosteroids should be used during pregnancy only if the potential benefit justifies potential risk to the fetus. Drugs of this class should not be used on pregnant patients in large amounts or for prolonged periods of time. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in the breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

The following local adverse reactions have been reported infrequently with the use of topical corticosteroids: Irritation, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae and miliaria.
Lotion: Local adverse reactions rarely reported include burning, folliculitis, acneiform reaction, pruritus and signs of skin atrophy.
Cream: Local adverse reactions very rarely reported include paresthesia, pruritus and signs of skin atrophy.
Ointment: Local adverse reactions rarely reported include pruritus, burning, tingling and/or stinging and signs of skin atrophy.

Store at 2°-30°C.

Topical Corticosteroids

D07AC13 - mometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.

G

Lotion 0.1% x 10 mL. Cream 0.1% x 5 g, 10 g. Oint 0.1% x 10 g.